The announcement came after GSK said on Jan. 15 that Unilever’s bid was unsolicited and undervalued the consumer healthcare business.
Unilever said it understood GSK’s value, but remained committed to its bid, as the company is “committed to maintaining strict financial discipline to ensure that acquisitions create value for our shareholders,” according to the article.
In a response to The Wall Street Journal, Unilever said it remains committed to building a future in the consumer healthcare business.
